GlassScriptPhysician profile
Christopher J Lyon
NPI 1497076525
$2,391.06
in general payments reported to CMS, 2019-2025
14 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $216 · 2024: $848 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.08 |
| Education | $111.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $569.35 | 2023-2025 | Tremfya |
| Abbvie INC. | $501.65 | 2023-2025 | |
| Amgen INC. | $283.93 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $237.69 | 2024-2025 | |
| Ucb, INC. | $203.12 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $120.03 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $114.62 | 2024-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $90.60 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $75.35 | 2025 | Dupixent, Libtayo |
| Genzyme Corporation | $72.81 | 2023-2025 | |
| Mayne Pharma Commercial LLC | $41.27 | 2024-2025 | |
| Dilon Technologies, INC. | $29.64 | 2025 | Hemoblast Bellows |
| Botanix Sb INC | $26.64 | 2025 | Sofdra |
| Leo Pharma INC. | $24.36 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.